ITMI20121774A1 - USE OF A BIOACTIVATED PHYTOCHIMIC AS A NEUROPROTECTIVE AGENT FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES RELATED TO THE NERVOUS SYSTEM - Google Patents

USE OF A BIOACTIVATED PHYTOCHIMIC AS A NEUROPROTECTIVE AGENT FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES RELATED TO THE NERVOUS SYSTEM

Info

Publication number
ITMI20121774A1
ITMI20121774A1 IT001774A ITMI20121774A ITMI20121774A1 IT MI20121774 A1 ITMI20121774 A1 IT MI20121774A1 IT 001774 A IT001774 A IT 001774A IT MI20121774 A ITMI20121774 A IT MI20121774A IT MI20121774 A1 ITMI20121774 A1 IT MI20121774A1
Authority
IT
Italy
Prior art keywords
phytochimic
bioactivated
prevention
treatment
nervous system
Prior art date
Application number
IT001774A
Other languages
Italian (it)
Inventor
Placido Bramanti
Nicola Gina Rosalinda De
Renato Iori
Emanuela Mazzon
Original Assignee
Placido Bramanti
Nicola Gina Rosalinda De
Renato Iori
Emanuela Mazzon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Placido Bramanti, Nicola Gina Rosalinda De, Renato Iori, Emanuela Mazzon filed Critical Placido Bramanti
Priority to IT001774A priority Critical patent/ITMI20121774A1/en
Priority to EP13791744.9A priority patent/EP2908850B1/en
Priority to PCT/EP2013/071706 priority patent/WO2014060509A1/en
Publication of ITMI20121774A1 publication Critical patent/ITMI20121774A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT001774A 2012-10-19 2012-10-19 USE OF A BIOACTIVATED PHYTOCHIMIC AS A NEUROPROTECTIVE AGENT FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES RELATED TO THE NERVOUS SYSTEM ITMI20121774A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT001774A ITMI20121774A1 (en) 2012-10-19 2012-10-19 USE OF A BIOACTIVATED PHYTOCHIMIC AS A NEUROPROTECTIVE AGENT FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES RELATED TO THE NERVOUS SYSTEM
EP13791744.9A EP2908850B1 (en) 2012-10-19 2013-10-17 A composition comprising glucoraphanin, myrosinase and a buffered solution for use in the treatment of neurodegenerative diseases
PCT/EP2013/071706 WO2014060509A1 (en) 2012-10-19 2013-10-17 Use of a bioactivated phytochemical as a neuroprotective agent for preventing and treating disorders related to nervous system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001774A ITMI20121774A1 (en) 2012-10-19 2012-10-19 USE OF A BIOACTIVATED PHYTOCHIMIC AS A NEUROPROTECTIVE AGENT FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES RELATED TO THE NERVOUS SYSTEM

Publications (1)

Publication Number Publication Date
ITMI20121774A1 true ITMI20121774A1 (en) 2014-04-20

Family

ID=47388542

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001774A ITMI20121774A1 (en) 2012-10-19 2012-10-19 USE OF A BIOACTIVATED PHYTOCHIMIC AS A NEUROPROTECTIVE AGENT FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES RELATED TO THE NERVOUS SYSTEM

Country Status (3)

Country Link
EP (1) EP2908850B1 (en)
IT (1) ITMI20121774A1 (en)
WO (1) WO2014060509A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116474079A (en) * 2019-05-08 2023-07-25 深圳福山生物科技有限公司 Composition containing glucoraphanin and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091087A1 (en) * 2000-07-05 2002-07-11 Yuesheng Zhang Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
WO2003051313A2 (en) * 2001-12-18 2003-06-26 Brassica Foundation For Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
WO2009083871A1 (en) * 2007-12-20 2009-07-09 Alma Mater Studiorum - Universita' Di Bologna Combination between an isothiocyanate and levodopa for parkinson's disease treatment
EP2213280A1 (en) * 2009-01-30 2010-08-04 DSM IP Assets B.V. Formulations comprising glucosinolate and myrosinase
WO2012037193A2 (en) * 2010-09-17 2012-03-22 Brassica Protection Products Llc Formulations for treatment with glucosinolate
WO2012074412A1 (en) * 2010-11-29 2012-06-07 Comvita New Zealand Limited Cancer chemoprotective product comprising glucoraphanin and/or glucoraphanen compound and myrosinase enzyme from brassicaceae plant sources
US20120213890A1 (en) * 2011-02-22 2012-08-23 Caudill Seed Company, Inc. Spray dried myrosinase and use to produce isothiocynates
US20120258922A1 (en) * 2011-04-08 2012-10-11 Seminis Vegetable Seeds, Inc. Synergistic inhibition of low-density lipoprotein oxidation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091087A1 (en) * 2000-07-05 2002-07-11 Yuesheng Zhang Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
WO2003051313A2 (en) * 2001-12-18 2003-06-26 Brassica Foundation For Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
WO2009083871A1 (en) * 2007-12-20 2009-07-09 Alma Mater Studiorum - Universita' Di Bologna Combination between an isothiocyanate and levodopa for parkinson's disease treatment
EP2213280A1 (en) * 2009-01-30 2010-08-04 DSM IP Assets B.V. Formulations comprising glucosinolate and myrosinase
WO2012037193A2 (en) * 2010-09-17 2012-03-22 Brassica Protection Products Llc Formulations for treatment with glucosinolate
WO2012074412A1 (en) * 2010-11-29 2012-06-07 Comvita New Zealand Limited Cancer chemoprotective product comprising glucoraphanin and/or glucoraphanen compound and myrosinase enzyme from brassicaceae plant sources
US20120213890A1 (en) * 2011-02-22 2012-08-23 Caudill Seed Company, Inc. Spray dried myrosinase and use to produce isothiocynates
US20120258922A1 (en) * 2011-04-08 2012-10-11 Seminis Vegetable Seeds, Inc. Synergistic inhibition of low-density lipoprotein oxidation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAN JI MAN ET AL: "Protective effect of sulforaphane against dopaminergic cell death", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 321, no. 1, 1 April 2007 (2007-04-01), pages 249 - 256, XP002518062, ISSN: 0022-3565, DOI: 10.1124/JPET.106.110866 *
KELSEY NATALIE A ET AL: "Nutraceutical antioxidants as novel neuroprotective agents.", MOLECULES (BASEL, SWITZERLAND) NOV 2010, vol. 15, no. 11, November 2010 (2010-11-01), pages 7792 - 7814, XP002690919, ISSN: 1420-3049 *
MORRONI ET AL.: "Sulforaphane improves impairments and protects against neuron death in a mouse model of Parkinson's disease", 14 September 2011 (2011-09-14), XP002690918, Retrieved from the Internet <URL:http://cong35.sifweb.org/congresso_abs_view.php?id=542> [retrieved on 20130122] *
PING Z ET AL: "Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1343, 9 July 2010 (2010-07-09), pages 178 - 185, XP027096579, ISSN: 0006-8993, [retrieved on 20100424] *
ZHAO J ET AL: "Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 393, no. 2-3, 30 January 2006 (2006-01-30), pages 108 - 112, XP027885485, ISSN: 0304-3940, [retrieved on 20060130] *

Also Published As

Publication number Publication date
WO2014060509A1 (en) 2014-04-24
EP2908850B1 (en) 2018-03-07
EP2908850A1 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
ZA202003200B (en) Compositions, methods, and systems for the synthesis and use of imaging agents
HK1218110A1 (en) Sulfamoyl arylamides and the use thereof as medicaments for the treatment of hepatitis b
HK1208465A1 (en) Sulfamoyl arylamides and the use thereof as medicaments for the treatment of hepatitis b
HK1254470A1 (en) 3&#39; equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals
IL236054A0 (en) Compositions and methods for treating crohn&#39;s disease and related conditions and infections
HK1207382A1 (en) Methods for the synthesis of ethylfumarates and their use as intermediates
HK1204461A1 (en) Compositions and methods of use of phorbol esters for the treatment of stroke
IL238611A0 (en) Benzomorphan analogs and the use thereof
HUE053113T2 (en) 2,2-difluoropropionamide derivative of bardoxolone methyl, pharmaceutical compositions and polymorphs thereof for use in treating certain conditions
IL235734A0 (en) &#34; process for the preparation of treprostinil and derivatives thereof&#39;
HK1212628A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation -cxcl9-cxcl10-cxcl11-cxcl13-cxcr3 -cxcr5
HRP20181879T1 (en) Compounds for the treatment of obesity and methods of use thereof
HK1246694A1 (en) Use of thymosin alpha for the treatment of sepsis
HK1215794A1 (en) Allogeneic autophagosome-enriched composition for the treatment of disease
HK1201270A1 (en) Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides -5---5--
ITMI20121774A1 (en) USE OF A BIOACTIVATED PHYTOCHIMIC AS A NEUROPROTECTIVE AGENT FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES RELATED TO THE NERVOUS SYSTEM
HUE056121T2 (en) Composition for increasing the effectiveness of uv-b therapy, process for the preparation thereof, and its use
HK1189513A1 (en) Topical formulations for the prevention of sexually transmitted disease and methods of producing the same
ITVI20120131A1 (en) DEFORMATION COMPENSATOR DEVICE FOR FIXTURES AS WELL-BEING STRUCTURE INCLUDING THIS DEVICE